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Abstract 
Numerous studies have investigated aripiprazole as a treatment for bipolar disorder 
(BD). therefore we conducted this comprehensive meta-analysis to investigate the 
efficacy and safety profile of aripiprazole in treating BD. Two authors conducted 
systematic searches of PubMed and ScienceDirect from inception until May 14 th, 
2017. Randomized controlled trials (RCTs) of people with BD who received 
aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including 
two which investigated the efficacy of aripiprazole versus haloperidol 
(aripiprazole=340; haloperidol=337), three which compared aripiprazole versus 
lithium (aripiprazole=208; lithium=212), and 15 with multiple comparisons of 
aripiprazole versus a placebo (aripiprazole=1923; placebo=1499). Compared to a 
placebo, aripiprazole improved acute mania (Hedges’ g: -0.299, p=0.001) and 
psychosis (Hedges’ g: -0.296, p<0.001) in the acute mania state, but did not improve 
depressive symptoms (Hedges’ g: -0.127, p=0.054) in the acute depressive state. 
Aripiprazole was associated with lower relapse rates  in bipolar mania when used in 
combination versus a placebo in maintenance therapy (odds ratio: 0.522, p<0.029). 
Aripiprazole was also associated with higher levels of high density lipoprotein, lower 
dropout rates, but no difference in extrapyramidal symptoms in the maintenance 
phase versus a placebo or in comparison with other medications (haloperidol or 
lithium). Our results suggest that aripiprazole is effective and safe in treating  bipolar 
mania. Further trials are necessary to evaluate the efficacy and tolerability versus 
other medications. 
 
Keywords: Aripiprazole; bipolar disorder; efficacy; tolerability; meta-analysis 
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Introduction  
Bipolar disorder (BD) affects approximately 2.4% of the general population 
(Merikangas et al., 2011) and is easily misdiagnosed or under-diagnosed (Angst, 
2006). BD is associated with a greatly impaired quality of life, increased physical 
health burden (Vancampfort et al., 2016; Vancampfort et al., 2015) and disability 
(Hirschfeld et al., 2003; Yatham et al., 2004). Moreover, BD can impact employment 
(Reed et al., 2010) and lead to lower self-esteem (Nilsson et al., 2010) and reduced 
social interaction (Judd and Akiskal, 2003). Furthermore, approximately 23% of 
patients with BD report a history of suicide attempts (Kattimani et al., 2016) 
 BD has a complicated, multifactorial etiology including genetic, neuro-endocrine, 
and environmental factors (Craddock and Sklar, 2013). Pharmacological therapy is 
often the first-line treatment for BD, followed by psychological (Oud et al., 2016) and 
psychosocial interventions (Goodwin et al., 2008). In addition to lithium and 
anticonvulsants (van der Loos et al., 2011; Yildiz et al., 2015), antipsychotic agents 
have also shown promising efficacy for bipolar mania (Yildiz et al., 2011) and 
depression (Goodwin et al., 2016). 
Aripiprazole, a novel antipsychotic agent combining partial agonist activity at 
dopamine-2 (D2), dopamine-3 (D3), and serotonin-1A (5-HT1A) receptors with 
antagonist activity at serotonin-2A (5-HT2A) and D2 receptors (Burris et al., 2002; 
Jordan et al., 2002). It has shown beneficial effects in patients with schizophrenia and 
possibly in mood disorders including BD, including good tolerability in patients with 
schizophrenia (Oya et al., 2015), good efficacy in patients with acute mania 
(Fountoulakis et al., 2011; Young et al., 2009), and good efficacy in preventing 
relapses (Marcus et al., 2011), although there is limited evidence regarding bipolar 
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depression (Vieta et al., 2010). Aripiprazole is known to have a beneficial metabolic 
profile, which is an important consideration given that these patients are at an 
increased risk of cardiometabolic disorders (Vancampfort et al., 2016; Vancampfort 
et al., 2015), although it may be associated with akathisia. 
Two previous meta-analyses (Brown et al., 2013; Meduri et al., 2016) 
investigated the efficacy or safety profile of aripiprazole. Brown et al (Brown et al., 
2013) discussed the efficacy and adverse reactions in BD; however, the authors only 
addressed the effects of treatment with regards to episodes of mania without 
considering the depression or maintenance phase, and their search only included 
trials before 2013. Furthermore, previous analysis of adverse reactions have 
contained less than three trials, precluding the ability to make definitive conclusions 
(Davey et al., 2011). Another more recent meta-analysis (Meduri et al., 2016) 
included 16 trials and observational studies of BD, however their analysis focused on 
the severity of changes in mania and response rates, and did not include subgroup 
analyses for depression, remission rates or relapse rates. Following these two 
meta-analyses, another two preliminary meta-analyses have also been published 
(Dundar et al., 2016; Lindstrom et al., 2017). Of them, the meta-analysis by Dundar 
et al (2016) focused on pharmacologic treatment for acute agitation but not regular 
treatment. Their results revealed that olanzapine was superior to haloperidol, and 
that no other treatment, including aripiprazole, was more effective than any other 
(Dundar et al., 2016). On the other hand, the meta-analysis by Lindstrom et al (2017), 
focused on the treatment effect of second-generation antipsychotics in the 
maintenance phase, and found that aripiprazole was beneficial in preventing 
relapses (Lindstrom et al., 2017). However, although their results showed statistical 
significance, the results for aripiprazole were based on only two datasets, thereby 
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limiting the strength of their meta-analysis (Davey et al., 2011). 
Given these gaps in the literature, we conducted this comprehensive systematic 
review and meta-analysis to investigate the efficacy and safety profile of aripiprazole 
in the treatment of BD, specifically focusing on sub-group analyses of depression, 
laboratory data, adverse reactions, and preventive efficacy of mood episodes 
including relapse rates. 
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Method and Materials  
The current meta-analysis was conducted according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Liberati et al., 
2009) (Supplement Table 1) following a pre-specified but unpublished protocol. This 
meta-analysis met the requirements of the Institutional Review Board of Tri-Service 
General Hospital (TSGHIRB: B-105-12). 
 
Inclusion criteria 
The inclusion criteria were: (1) published randomized controlled trials (RCTs) 
exploring the efficacy of aripiprazole as monotherapy or combination therapy versus 
a placebo or other antipsychotic medication; (2) articles including patients with the 
diagnosis of BD with either manic/mixed or depressed episodes based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria or International 
Classification of Diseases (ICD) codes; and (3) articles that were clinical trials 
including adult and adolescent populations, for whom aripiprazole has been 
approved to treat BD by the Food and Drug Administration (FDA) in the USA and the 
European Medicines Agency (EMA) in the EU. No limit was set for the length of study 
follow-up. The exclusion criteria were: (1) articles that were not controlled 
intervention studies; and (2) animal studies. 
 
Database searches and identification of eligible papers 
Two independent authors searched PubMed and ScienceDirect using the 
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keywords (aripiprazole) AND (bipolar disorder OR mania OR depress) from inception 
to May 14th, 2017 with the limitations of “humans; clinical trial” for PubMed and 
“bipolar disorder/antipsychotic; journal article” for ScienceDirect. In addition, the 
reference lists of review articles relevant to this topic were manually searched to 
identify potentially eligible papers (Arbaizar et al., 2009; Biederman et al., 2005; 
Brown et al., 2013; Fountoulakis et al., 2009; Fountoulakis et al., 2011; McKeage, 
2014; Meduri et al., 2016; Miura et al., 2014; Perlis, 2007; Perlis et al., 2006; Scherk 
et al., 2007; Smith et al., 2007; Taylor, 2003; Vieta et al., 2010; Yatham et al., 2013; 
Yildiz et al., 2015).  
After completing the searches, duplicate studies were removed, and two 
independent authors screened the titles and abstracts for eligibility. A list of 
potentially eligible studies was developed by consensus, and the full texts were 
assessed by the two authors. Both authors then applied the eligibility criteria and 
developed a final list of studies to be included. A third reviewer was available for 
mediation in the event of any inconsistencies. 
 
Methodological quality appraisal 
The methodological quality of the included studies was determined by two 
authors using the Jadad scale (Jadad et al., 1996). In brief, the Jadad score was 
calculated for each study and included three categories of study quality: 
randomization, blindness, and withdrawals and dropouts. The Jadad score ranged 
from zero (poor quality) to five (high quality). 
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Primary outcomes 
The primary outcomes were differences in changes of measures of mania, 
depression, relapse rates, or general severity as measured using the Clinical Global 
Impressions Scale-Severity (CGI-S) from pre-treatment to post-treatment between 
aripiprazole and a placebo or other medications (haloperidol or lithium). The 
outcomes of interest had to be recorded using a validated scale such as the Hamilton 
Rating Scale for Depression (17-items) (HAM-D-17) (Williams, 1988) or 
Montgomery-Åsberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 
1979) for depressive symptoms, and Young Mania Rating Scale (YMRS) for mania 
symptoms (Young et al., 1978).  
 
Secondary outcomes 
The secondary outcomes of interest included response rates, remission rates, 
drop-out rates, rates of discontinuation of trials due to side effects, cognitive 
subscales of the Positive and Negative Syndrome Scale (PANSS), and the incidence of 
any adverse reactions. Other measurements of disease severity including the PANSS 
(Kay et al., 1987) for psychotic features, and CGI-S (Busner and Targum, 2007) for 
mania or depression were also recorded.  
Response was defined as ≥ 50% reduction from baseline in YMRS total score 
(Jeong et al., 2012) or ≥ 50% decrease from baseline in MADRS total score (Thase et 
al., 2008). Remission was defined as a MADRS total score ≤ 8 (Thase et al., 2008), 
YMRS total score ≤ 12 or CGI-S ≤ 2 (El Mallakh et al., 2010; Findling et al., 2009). 
Relapse was defined as discontinuation of the study due to a lack of efficacy (Keck et 
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al., 2007), the need for hospitalization (Carlson et al., 2012; Jeong et al., 2012), YMRS 
total score ≥ 18 or MADRS total score ≥ 18 or ≥ 4-point increase from baseline 
(El-Mallakh et al., 2012), YMRS total score > 14 and a MADRS total score ≤ 16 for a 
relapse of a manic episode, a YMRS total score > 14 and a MADRS total score > 16 for 
a relapse of a mixed episode, and a YMRS total score ≤ 14 and a MADRS total score > 
16 for a relapse of a depressive episode (Thase et al., 2008).  
 
Data extraction and management 
Two independent authors extracted data from the eligible studies into a 
database. The variables of interest included mean age (years), age at onset, gender, 
duration of illness, treatment duration, dosage of prescribed aripiprazole, education, 
marriage status, occupation, ethnicity (Caucasian, Africa American, Hispanic, Asian, 
or Native America), Jadad score (Jadad et al., 1996), and all primary and secondary 
outcomes as listed above. When data were not available in the articles, we contacted 
the corresponding authors twice over a month-long period in an attempt to acquire 
the variables of interest.  
 
Meta-analysis 
Under the presumed heterogeneity of the sample populations among all of the 
recruited studies, the data were analyzed using random-effects meta-analysis 
models rather than fixed effect models (Borenstein et al., 2010) with Comprehensive 
Meta-Analysis software, version 3 (Biostat, Englewood, NJ). Continuous outcomes 
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were analyzed by calculating the effect sizes (ESs) as Hedges’ g and 95% confidence 
intervals (95% CIs) comparing outcomes between aripiprazole and a placebo or other 
psychotropic medications. Odds ratios (ORs) and 95% CIs were calculated for 
dichotomous data. When measuring the efficacy with regards to psychotic features, 
total PANSS scores were included into the analysis for a more complete evaluation, if 
the study provided both total PANSS and PANSS scores of positive symptoms. Data on 
adverse events were also pooled across studies and compared versus a placebo 
where possible. 
A two-tailed p value of less than 0.05 was considered to be statistically 
significant. Heterogeneity was assessed using the Q statistic to evaluate the 
dispersion of the true effect among the recruited studies  (Higgins et al., 2003). 
Publication bias was evaluated by visual inspection of funnel plots and Egger’s 
regression tests (Egger et al., 1997). In cases of publication bias, the trim and fill test 
was conducted to impute potential missing trials and re-calculate the effect size 
(Duval and Tweedie, 2000). Finally, meta-regression and subgroup meta-analyses 
were conducted to investigate the effects of clinical variables as possible sources of 
heterogeneity. Meta-regression analyses were performed using the unrestricted 
maximum likelihood method only when data were available across more than five 
studies. The variables of interest for meta-regression were mean age, female gender, 
body mass index (BMI), treatment duration, dosage of prescribed medications, 
duration of illness, education, marriage status, occupation, ethnicity (Caucasian, 
Africa American, Hispanic, Asian, or Native America), drop-out rate, and Jadad score. 
Subgroup meta-analysis was performed when at least three sets of data were 
available (Davey et al., 2011). Subgroup analyses included monotherapy or 
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combination therapy, acute or maintained course, and different categories of 
treatment doses in order to clarify the efficacy in clinical practice.  
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Results 
Study selection 
In the initial search, 373 studies were identified after removing duplicates (59 
from PubMed and 341 from ScienceDirect). After screening the titles/abstracts, 43 
full-text articles were assessed for eligibility, of which 22 were excluded (Figure 1 and 
Supplement Table 2). Therefore, 20 articles were eligible for the current 
meta-analysis (Carlson et al., 2012; El-Mallakh et al., 2012; El Mallakh et al., 2010; 
Findling et al., 2013; Findling et al., 2009; Findling et al., 2012; Jeong et al., 2012; 
Kanba et al., 2014; Keck et al., 2007; Keck et al., 2003; Keck et al., 2009; Muzina et al., 
2008; Quante et al., 2010; Sachs et al., 2006; Thase et al., 2008; Tramontina et al., 
2009; Vieta et al., 2005; Vieta et al., 2008; Woo et al., 2011; Young et al., 2009) (Table 
1). 
Among the 20 eligible articles, two investigated the efficacy of aripiprazole 
monotherapy in comparison with haloperidol (Vieta et al., 2005; Young et al., 2009) 
(aripiprazole participants = 340; haloperidol participants = 337). One article (Keck et 
al., 2009) compared aripiprazole monotherapy and lithium in the acute phase of 
illness (aripiprazole = 155; lithium = 160), another article (El-Mallakh et al., 2012) 
compared aripiprazole monotherapy versus lithium in the maintenance stage 
(aripiprazole = 25; lithium = 38), and another article (Jeong et al., 2012) investigated 
the combination of aripiprazole with valproic acid versus haloperidol with valproic 
acid (aripiprazole = 28; haloperidol = 14). The remaining 15 articles (Carlson et al., 
2012; El Mallakh et al., 2010; Findling et al., 2013; Findling et al., 2009; Findling et al., 
2012; Kanba et al., 2014; Keck et al., 2007; Keck et al., 2003; Muzina et al., 2008; 
Quante et al., 2010; Sachs et al., 2006; Thase et al., 2008; Tramontina et al., 2009; 
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Vieta et al., 2008; Woo et al., 2011) compared aripiprazole 
monotherapy/combination therapy with a placebo in the acute or maintenance stage 
(aripiprazole = 1923; placebo = 1499). 
 
Methodological quality of the included studies 
Across the 20 studies, the average Jadad score was 3.35 with a standard 
deviation (SD) of 0.49 (Supplementary Table 3). 
 
Meta-analysis investigating the effect of aripiprazole on BD compared to a placebo 
or other medication  
1. Meta-analysis comparing the treatment efficacy of aripiprazole monotherapy 
and a placebo in the acute stage of BD 
1.1. Primary outcome: comparing treatment efficacy for depression and mania  
1.1.1. Treatment efficacy for depression   
Across four articles (Findling et al., 2009; Sachs et al., 2006; Tramontina et al., 
2009; Young et al., 2009), there was no significant difference in treatment effect 
between aripiprazole monotherapy (case number, n = 519 in five comparative arms) 
and a placebo (n = 412 in four arms) for the acute stage of bipolar depression 
(Hedges’ g: -0.127, 95% CI: -0.257 to 0.002, p = 0.054, RCTs = 4 with five datasets) 
(Figure 2A). There was no significant heterogeneity (Q value = 4.41, df = 4, p = 0.353; 
I2 = 9.287%, tau = 0.046) or publication bias according to Egger’s test (t = 0.512, df = 3, 
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2-tailed p = 0.644). Following a sensitivity test and removal of the study by Young et 
al (Young et al., 2009), aripiprazole was found to be more effective in treating 
depression versus a placebo (Hedges’ g: -0.208, 95% CI: -0.355 to -0.061, p = 0.006). 
We did not perform further subgroup meta-analysis of trials with adults only as 
fewer than three datasets were available (Sachs et al., 2006; Young et al., 2009). We 
divided the trials into two categories by daily dosage (< 20 mg/day and > 20 mg/day) 
to evaluate whether or not there was a dose-dependent effect. Only two studies 
used a dose of < 20 mg/day, thus precluding meta-analysis (Findling et al., 2009; 
Tramontina et al., 2009). Across three RCTs, no significant difference between 
aripiprazole (n = 403 in three arms) and placebo (n = 387 in three arms) was noted in 
the > 20 mg/day group (Findling et al., 2009; Sachs et al., 2006; Young et al., 2009) 
(Hedges’ g: -0.097, 95% CI: -0.279 to 0.086, p = 0.299).  
Meta-regression analysis showed that age, female sex, dosage of aripiprazole, 
ethnicity (Caucasian), and Jadad scores (randomization, blind, total) were all 
non-significant (data not shown, available on request).  
 
1.1.2 Treatment efficacy and relapse rates for mania 
To determine the efficacy for mania, five articles (El Mallakh et al., 2010; 
Findling et al., 2009; Sachs et al., 2006; Tramontina et al., 2009; Young et al., 2009) 
were eligible for the analysis. Aripiprazole monotherapy (n = 786 in seven arms) was 
significantly superior to placebo (n = 546 in five arms) in treating mania (Hedges’ g: 
-0.299, 95% CI: -0.476 to -0.123, p = 0.001) (Figure 2B). Egger`s regression test 
showed no significant publication bias (t = 1.519, df = 5, 2-tailed p = 0.189); however, 
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heterogeneity was significant (Q value = 17.51, df = 6, p = 0.008; I2 = 65.73%, tau = 
0.188). With regards to sensitivity, the significance of the results did not change after 
removing any one of the recruited studies. 
The results of subgroup meta-analysis of trials with adults only revealed no 
significant difference in the treatment effect on manic symptoms between 
aripiprazole and a placebo (Hedges’ g: -0.162, 95% CI: -0.328 to 0.003, p = 0.055) (El 
Mallakh et al., 2010; Sachs et al., 2006; Young et al., 2009). However, after removing 
data from El Mallakh et al’s study (2010) which included aripiprazole 15 mg only (El 
Mallakh et al., 2010), the results showed a significantly better treatment effect on 
manic symptoms in the aripiprazole arms than in the placebo arms (Hedges’ g: -0.218, 
95% CI: -0.392 to -0.043, p = 0.014). In addition, in the lower dose group (< 20 
mg/day) (El Mallakh et al., 2010; Findling et al., 2009; Tramontina et al., 2009), 
aripiprazole (n = 247 in three arms) was not effective compared with a placebo (n = 
258 in three arms) (Hedges’ g: -0.386, 95% CI: -0.859 to -0.087, p = 0.109). However, 
in the higher dose group (> 20 mg/day) (El Mallakh et al., 2010; Findling et al., 2009; 
Sachs et al., 2006; Young et al., 2009), aripiprazole (n = 539 in four arms) was 
superior to a placebo in treating mania (n = 521 in four arms) (Hedges’ g: -0.272, 95% 
CI: -0.444 to -0.101, p = 0.002). 
It was possible to perform subgroup meta-analysis of studies of a shorter 
duration (< 4 weeks) (El Mallakh et al., 2010; Young et al., 2009), and the results 
revealed no significant difference between aripiprazole (n = 434 in three arms) and a 
placebo (n = 287 in two arms) (Hedges’ g: -0.097, 95% CI: -0.231 to 0.037, p = 0.157). 
There were insufficient data for studies of a longer treatment duration (> 4 weeks) 
since only one article (Tramontina et al., 2009) met the inclusion criteria. 
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For relapse rates of mania, three datasets from two articles (Thase et al., 2008; 
Young et al., 2009) revealed no significant difference (OR: 0.829, 95% CI: 0.407 to 
1.688, p = 0.605) between aripiprazole (n=538 in 3 arms) and a placebo (n = 529 in 
three arms) without significant heterogeneity (Q value = 0.718, df = 2, p = 0.698; I2 < 
0.001%, tau < 0.001) but significant publication bias (t value = 135.796, df = 1, p = 
0.005). However, after the trim and fill test (with two potentially missing studies to 
the left of the mean), no change in the results of meta-analysis was noted (OR: 0.650, 
95% CI: 0.358 to 1.180, p = 0.157). In addition, no change was noted in a sensitivity 
analysis after removing one study. 
In meta-regression analysis, older age was positively correlated with a greater 
effect size (coefficient = 0.0137, p = 0.0081) in treatment efficacy for mania. No 
relationship was noted for other variables (female sex, status of BD (percentage of 
manic mood state, rapid-cycling, or mixed episodes), dosage of aripiprazole, and 
ethnicity (Caucasian, Hispanic). 
 
1.2 Secondary outcomes: other measurements of efficacy and adverse reactions 
1.2.1 Efficacy profile: response rates, remission rates, and other measurements of 
severity (CGI-S, PANSS)  
There were insufficient data to analyze response rates or remission rates for 
depression. In three articles which reported remission rates for mania (Findling et al., 
2009; Tramontina et al., 2009; Young et al., 2009), aripiprazole was significantly more 
effective than a placebo (OR: 4.893, 95% CI: 1.373 to 17.432, p = 0.014) with 
significant heterogeneity (Q value = 25.721, df = 3, p < 0.001; I2 = 88.336%, tau = 
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1.201) with no significant publication bias (t value = 2.344, df = 2, p = 0.144). The 
significance of the results became non-significant after removing the dataset of 
Findling et al (10 mg aripiprazole/day) (OR: 4.689, 95% CI: 0.858 to 25.618, p = 0.075) 
(Findling et al., 2009) or Tramontina et al (OR: 4.786, 95% CI: 0.987 to 23.214, p = 
0.052) (Tramontina et al., 2009). Response rates for mania were reported in five 
articles (El Mallakh et al., 2010; Findling et al., 2009; Sachs et al., 2006; Tramontina et 
al., 2009; Young et al., 2009), and aripiprazole was significantly better than a placebo 
(OR: 2.054, 95% CI: 1.366 to 3.089, p = 0.001) with significant heterogeneity (Q value 
= 21.062, df = 6, p = 0.002; I2 = 71.513%, tau = 0.450) but no significant publication 
bias (t value = 1.625, df = 5, p = 0.165). The results did not change after the removal 
of one study. 
The CGI-S was used to estimate the general severity of illness for mania, 
depressed or mixed episodes across nine articles (El Mallakh et al., 2010; Findling et 
al., 2009; Kanba et al., 2014; Keck et al., 2003; Keck et al., 2009; Sachs et al., 2006; 
Thase et al., 2008; Tramontina et al., 2009; Young et al., 2009). After treatment, 
aripiprazole was associated with a greater improvement in CGI-S scores than a 
placebo (Hedges’ g: -0.322, 95% CI: -0.418 to -0.225, p < 0.001) without evidence of 
heterogeneity (Q value = 16.678, df = 10, p = 0.082; I2 = 40.040%, tau = 0.102) but 
with significant publication bias (t value = 2.317, df = 9, p = 0.046). However, after the 
trim and fill test (with two potentially missing studies to the right of the mean), the 
results of the meta-analysis did not change (Hedges’ g: -0.293, 95% CI: -0.391 to 
-0.195, p < 0.001). The results did not change after the removal of one study. 
In four articles (Kanba et al., 2014; Keck et al., 2009; Sachs et al., 2006; Young et 
al., 2009), aripiprazole was more effective than a placebo in improving psychotic 
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features (Hedges’ g: -0.296, 95% CI: -0.411 to -0.181, p < 0.001). No significant 
heterogeneity was noted (Q value = 0.101, df = 3, p = 0.992; I2 < 0.001%, tau < 0.001) 
although there was evidence of publication bias (t value = 12.390, df = 2, p = 0.006). 
However, the trim and fill test (with two potentially missing studies to the right of the 
mean) did not change the main result (Hedges’ g: -0.288, 95% CI: -0.393 to -0.184, p 
< 0.001). No change in the result was noted after the removal of one study. 
 
Adverse outcomes and dropout rates 
1.2.2 Metabolic profile: fasting glucose, BMI, body weight, high density lipoprotein 
(HDL), total cholesterol, triglyceride (TG), and increased appetite 
Compared to a placebo, aripiprazole was associated with a lower risk of elevated 
fasting glucose (Hedges’ g: 0.447, 95% CI: 0.048 to 0.846, p = 0.028, RCTs = 2 with 
three datasets), increased appetite (OR: 2.114, 95% CI: 1.058 to 4.226, p = 0.034, 
RCTs = 2 with four datasets), and total cholesterol (OR: 1.686, 95% CI: 1.032 to 2.754, 
p = 0.037, RCTs = 2 with three datasets). No significant differences were noted 
between aripiprazole and a placebo in changes in BMI (Hedges’ g: 0.170, 95% CI: 
-0.017 to 0.357, p = 0.074, RCTs = 2 with three datasets) and body weight (Hedges’ g: 
0.051, 95% CI: -0.109 to 0.210, p = 0.535, RCTs = 4 with five datasets). Furthermore, 
aripiprazole did not affect levels of high density lipoprotein (HDL) (Hedges’ g: -0.233, 
95% CI: -0.488 to 0.022, p = 0.074, RCTs = 2 with three datasets) or TG (Hedges’ g: 
0.082, 95% CI: -0.064 to 0.228, p = 0.273, RCTs = 2 with three datasets) compared to 
a placebo (Table 3). 
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1.2.3 Adherence profile: dropout rates and rates of discontinuation due to side 
effects 
There was no significant difference in dropout rate due to any reason between 
aripiprazole and a placebo (OR: 0.923, 95% CI: 0.723 to 1.178, p = 0.521, RCTs = 9 
with 12 datasets). In contrast, aripiprazole was associated with higher rates of 
discontinuation due to side effects compared to a placebo (OR: 1.551, 95% CI: 1.155 
to 2.082, p = 0.004, RCTs = 8 with 11 datasets) (Table 3). 
 
1.2.4 Gastro-intestinal profile (constipation, diarrhea, nausea, vomiting, dyspepsia) 
Aripiprazole was associated with higher rates of constipation (OR: 1.720, 95% CI: 
1.251 to 2.365, p = 0.001, RCTs = 6 with nine datasets), nausea (OR: 1.816, 95% CI: 
1.427 to 2.310, p < 0.001, RCTs = 7 with 10 datasets), and vomiting (OR: 2.083, 95% 
CI: 1.354 to 3.203, p = 0.001, RCTs = 6 with nine datasets) compared to a placebo. 
However, there were no significant differences in diarrhea (OR: 0.956, 95% CI: 0.694 
to 1.319, p = 0.785, RCTs = 5 with seven datasets) and dyspepsia (OR: 1.444, 95% CI: 
0.891 to 2.339, p = 0.136, RCTs = 4 with six datasets) between aripiprazole and a 
placebo (Table 3). 
 
1.2.5 Other adverse events: agitation, akathisia, anxiety, dizziness, over-sedation, 
light headedness, headache, fatigue, insomnia, pain in the extremities, and profile 
of extrapyramidal symptoms (EPS and sialorrhea) 
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Higher incidence rates of akathisia (OR: 5.104, 95% CI: 3.733 to 6.980, p < 0.001, 
RCTs = 8 with 11 datasets), anxiety (OR: 1.526, 95% CI: 1.058 to 2.203, p = 0.024, RCTs 
= 4 with six datasets), EPS (Hedges’ g: 0.538, 95% CI: 0.070 to 1.007, p = 0.024 , RCTs 
= 4 with five datasets), hyper-salivation (OR: 4.696, 95% CI: 1.535 to 14.369, p = 
0.007, RCTs = 2 with three datasets), fatigue (OR: 2.272, 95% CI: 1.443 to 3.577, p < 
0.001, RCTs = 2 with four datasets), insomnia (OR: 1.496, 95% CI: 1.028 to 2.177, p = 
0.035, RCTs = 5 with seven datasets), over-sedation (OR: 3.607, 95% CI: 2.267 to 
5.739, p < 0.001, RCTs = 5 with seven datasets), and pain in the extremities (OR: 
2.281, 95% CI: 1.260 to 4.127, p = 0.006, RCTs = 2 with three datasets) were observed 
with aripiprazole than with a placebo. However, there were no significant differences 
between aripiprazole and a placebo in dizziness (OR: 1.361, 95% CI: 0.719 to 2.575, p 
= 0.344, RCTs = 2 with four datasets), agitation (OR: 1.079, 95% CI: 0.773 to 1.508, p = 
0.654, RCTs = 3 with four datasets), headache (OR: 1.029, 95% CI: 0.857 to 1.235, p = 
0.762, RCTs = 8 with 11 datasets), and light headedness (OR: 1.108, 95% CI: 0.737 to 
1.666 p = 0.621, RCTs = 3 with four datasets) (Table 3). 
 
2. Meta-analysis comparing the treatment efficacy of aripiprazole monotherapy 
and a placebo in the maintenance stage of BD 
2.1. Primary outcome: rates of total relapse and general severity (CGI-S)   
Data were available from three studies to analyze the treatment efficacy during 
the maintenance phase (Findling et al., 2013; Keck et al., 2007; Muzina et al., 2008). 
In two of the articles (Findling et al., 2013; Keck et al., 2007), aripiprazole (n= 185 in 
three arms) was significantly superior to a placebo (n = 91 in two arms) in reducing 
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CGI-S (Hedges’ g: -0.483, 95% CI: -0.674 to -0.292, p < 0.001) (Figure 2C) without 
significant heterogeneity (Q value = 1.436, df = 2, p = 0.488; I2 < 0.001%, tau < 0.001) 
or publication bias (t value = 9.461, df = 1, p = 0.067). The results were unchanged 
after the removal of one study. 
We could not perform further meta-analysis of total relapse rate in the 
maintenance stage of aripiprazole monotherapy and placebo monotherapy because 
only two studies contained relevant data (Keck et al., 2007; Muzina et al., 2008). In 
these studies, the total relapse rates were significantly lower in the aripiprazole 
group than in the placebo group in the study by Keck et al (2007) (33% in the 
aripiprazole group and 52% in the placebo group) (Keck et al., 2007), and in the study 
by Muzina et al the time to relapse was significantly longer in the aripiprazole group 
than in the placebo group at week 100 (hazard ratio = 0.18, log-rank p = 0.017) 
(Muzina et al., 2008). 
 
2.2 Secondary outcome: other measurements of efficacy and adverse reactions 
2.2.1 Metabolic profile: fasting glucose, body weight, HDL, total cholesterol, and TG 
No significant differences were noted between treatment with aripiprazole and 
a placebo in fasting glucose (Hedges’ g: 0.169, 95% CI: -0.013 to 0.361, p = 0.069, 
RCTs = 3 with four datasets), increase in body weight (OR: 2.228, 95% CI: 0.856 to 
5.801, p = 0.101, RCTs = 2 with three datasets), change in total cholesterol (Hedges’ g: 
0.179, 95% CI: -0.156 to 0.514, p = 0.295, RCTs = 3 with four datasets), and changes in 
TG (Hedges’ g: 0.013, 95% CI: -0.606 to 0.631, p = 0.968, RCTs = 3 with four datasets). 
However, aripiprazole was associated with an increased level of HDL compared to a 
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placebo (Hedges’ g: -0.710, 95% CI: -1.165 to -0.254, p = 0.002, difference in means = 
-2.622, 95% CI: -4.370 to -0.875, RCTs = 3 with four datasets) (Table 3).  
 
2.2.2 Adherence profile: dropout rates, and rates of discontinuation due to side 
effects 
Aripiprazole was associated with significantly higher rates of discontinuation of 
treatment due to side effects compared to a placebo (OR: 7.897, 95% CI: 1.740 to 
35.848, p = 0.007, RCTs = 3 with four datasets). On the other hand, aripiprazole was 
associated with a significantly lower dropout rate compared to a placebo (OR: 0.417, 
95% CI: 0.249 to 0.696, p = 0.001, RCTs = 3 with four datasets) (Table 3). 
 
2.2.3 Gastro-intestinal profile: diarrhea, nausea, and  dry mouth 
Aripiprazole was associated with significantly higher rates of diarrhea (OR: 7.472, 
95% CI: 1.322 to 42.234, p = 0.023, RCTs = 2 with three datasets), and dry mouth (OR: 
5.801, 95% CI: 1.473 to 22.839, p = 0.012, RCTs = 3 with four datasets) compared to a 
placebo (Table 3). 
 
2.2.4 Other adverse events: akathisia, back pain, over-sedation, headache, tremor, 
EPS, and upper respiratory tract infection 
Aripiprazole was associated with a significantly higher rate of akathisia (OR: 
7.711, 95% CI: 2.162 to 27.499, p = 0.002, RCTs = 3 with four datasets) compared to a 
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placebo. However, there were no significant differences in the rates of headache (OR: 
1.501, 95% CI: 0.853 to 2.641, p = 0.159, RCTs = 2 with three datasets) and upper 
respiratory-tract infection (OR: 2.308, 95% CI: 0.925 to 5.763, p = 0.073, RCTs = 2 with 
three datasets) between aripiprazole and a placebo (Table 3). 
 
3. Meta-analysis comparing the treatment efficacy of aripiprazole combination 
therapy and a placebo in the acute or maintenance stage of BD  
3.1 Primary outcome: relapse rates for mania 
Only two articles compared aripiprazole in combination therapy in the acute 
phase of BD thus precluding meta-analysis (Quante et al., 2010; Vieta et al., 2008). 
Three trials (Carlson et al., 2012; Findling et al., 2012; Woo et al., 2011) were 
eligible in the maintenance phase with 248 patients in three arms receiving 
aripiprazole and 246 in three arms receiving a placebo. Aripiprazole tended to have a 
lower mania relapse rate (OR: 0.522, 95% CI: 0.291 to 0.937, p = 0.029) compared to 
a placebo without significant heterogeneity (Q value = 1.254, df = 2, p = 0.534; I2 < 
0.001%, tau < 0.001) or publication bias (t value = 0.477, df = 1, p = 0.717). After 
removal of the study by Carlson et al (Carlson et al., 2012) (OR: 0.453, 95% CI: 0.107 
to 1.926, p = 0.284) or Findling et al (Findling et al., 2012) (OR: 0.567, 95% CI: 0.310 
to 1.040, p = 0.067), the results were not significant. 
 
3.2 Secondary outcome: other measurements of adverse reactions 
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In terms of side effect profiles, aripiprazole was associated with a significantly 
greater increase in total cholesterol (difference in means: 2.000, 95% CI: 1.993 to 
2.007, p < 0.001, RCTs = 3 with three datasets). No significant differences were 
observed between aripiprazole and a placebo in changes in fasting glucose 
(difference in means: -1.967, 95% CI: -8.447 to 4.514, p = 0.552, RCTs = 3 with three 
datasets), changes in TG (difference in means: 3.238, 95% CI: -8.162 to 14.638, p = 
0.578, RCTs = 3 with three datasets), incidence of headache (OR: 0.721, 95% CI: 0.262 
to 1.983, p = 0.526, RCTs = 3 with three datasets) and dropout rate (OR: 0.748, 95% 
CI: 0.381 to 1.468, p = 0.398, RCTs = 3 with three datasets) (Table 3). 
 
4. Meta-analysis comparing the treatment efficacy of aripiprazole monotherapy 
or combination therapy with other medications (lithium or haloperidol) in the 
acute or maintenance stage of BD  
  Meta-analysis comparing the treatment efficacy of aripiprazole monotherapy 
and other medications during the maintenance phase was not possible becaus e only 
one article (El-Mallakh et al., 2012) contained sufficient relevant data. Another short 
trial (Jeong et al., 2012) did not have sufficient data for meta-analysis in the acute or 
maintenance phase of BD. 
 
4.1. Primary outcome: treatment efficacy for depressed symptoms, general 
severity (CGI-S), response rates, and manic symptoms  
Of three articles (Keck et al., 2009; Vieta et al., 2005; Young et al., 2009) with 
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data of the acute stage, aripiprazole monotherapy (n = 497 in three arms) did not 
significantly differ from other medications (haloperidol = 337 in two arms and lithium 
= 160 in one arm) in the treatment efficacy of depressed symptoms during the acute 
phase (Hedges’ g: -0.039, 95% CI: -0.193 to 0.115, p = 0.620). No significant 
heterogeneity (Q value = 3.085, df = 2, p = 0.214; I2 = 35.173%, tau = 0.081) or 
publication bias (t = 0.2854, df = 1, 2-tailed p = 0.823) were observed. The results 
were unchanged after the removal of one study. Furthermore, aripiprazole was 
significantly better than the other medications (haloperidol or lithium) in CGI-S 
(Hedges’ g: -0.191, 95% CI: -0.315 to -0.067, p = 0.003) without significant 
heterogeneity (Q value = 1.648, df = 2, p = 0.439; I2 < 0.001%, tau < 0.001) or 
publication bias (t = 0.044, df = 1, 2-tailed p = 0.972). Three articles reported the 
efficacy for mania symptoms (Keck et al., 2009; Vieta et al., 2005; Young et al., 2009), 
in which aripiprazole showed no significant difference in response rates (OR: 1.271, 
95% CI: 0.647 to 2.496, p = 0.486) compared to haloperidol or lithium. Subgroup 
analysis by medication (haloperidol vs. aripiprazole and lithium vs. aripiprazole) could 
not be performed because of insufficient data (less than three RCTs). 
 
4.2. Secondary outcome: other adverse reactions   
There were no significant differences between aripiprazole and other 
medications (haloperidol or lithium) in akathisia (OR: 0.789, 95% CI: 0.241 to 2.586, p 
= 0.696, RCTs = 3 with three datasets), dropout rate (OR: 0.812, 95% CI: 0.375 to 
1.759, p = 0.598, RCTs = 3 with three datasets), rates of discontinuation due to side 
effects (OR: 0.710, 95% CI: 0.212 to 2.378, p = 0.578, RCTs = 3 with three datasets), 
symptoms of EPS (Hedges’ g: -0.436, 95% CI: -1.032 to 0.159, p = 0.151, RCTs = 3 with 
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three datasets), headache (OR: 1.079, 95% CI: 0.748 to 1.555, p = 0.685, RCTs = 3 
with three datasets), and tremor (OR: 0.684, 95% CI: 0.433 to 1.082, p = 0.105, RCTs = 
3 with three datasets) (Table 3). 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
30 
 
Discussion 
To the best of our knowledge, this is first meta-analysis to comprehensively 
investigate the efficacy tolerability, and adverse reactions to aripiprazole from the 
acute to maintenance stage within bipolar manic/mixed state to bipolar depression. 
Comparison to two recent meta-analyses (Brown et al., 2013; Meduri et al., 2016), 
our study provided more information on the analysis of adverse reactions and 
preventive efficacy as shown by relapse rates from bipolar mania to bipolar 
depression. The more recent search dates and stricter inclusion criteria (only RCTs in 
this meta-analysis) mean that the results of this meta-analysis are more up-to-date 
compared to the previous reports. The main differences between the current study 
and the two previous meta-analyses are listed in Table 2. It should be noted that two 
(Findling et al., 2009; Tramontina et al., 2009) of the included articles reported the 
efficacy of BD in adolescents. In addition, the dose-dependent responses and 
adverse reactions to antipsychotic drugs should be considered with caution; however, 
aripiprazole has been approved for the treatment of BD in pediatric patients by the 
FDA in the USA and the EMA in the EU for its efficacy and safety. Furthermore, the 
previous two studies (Brown et al., 2013; Meduri et al., 2016) also included above 
two studies into their analyses. However, despite the apparent good tolerability, the 
results of this meta-analysis should be interpreted with caution for application in 
clinical practice in pediatric patients. 
To differentiate the does-effect from primary outcome, we set the cutoff point of 
a higher and lower dose at 20 mg/day. A previous meta-analysis (Brown et al., 2013) 
divided the enrolled trials into three groups at 10 mg/day, 15 mg/day, and 30 mg/day. 
However, in order to include more trials in each group, we only divided them into 
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two groups. Furthermore, an animal study (Li et al., 2004) demonstrated that a 
higher dose (30 mg/kg) in rodents could act as an antagonist to decrease cortical 
dopamine release, whereas a lower dose (0.3 mg/kg) would increase dopamine 
release in the medial prefrontal cortex and hippocampus. Setting a relatively higher 
cut-off point of 20 mg/day could prevent the effect of dopamine agonism with 
aripiprazole, although no human trials have replicated this finding. 
We summarized the efficacy of treating depression with aripiprazole. There was 
no significant difference in the efficacy between aripiprazole monotherapy and a 
placebo for acutely bipolar depression, although there was an insignificant trend 
favoring aripiprazole (effect size: -0.127, p = 0.054). However, its efficacy reached 
statistical significance when removing the study by Young et al (Young et al., 2009) 
during the sensitivity test. This may be due to the relatively large sample (n = 320) 
compared to other studies (n = 272 in Sachs et al; 43 in Tramontina et al; 296 in 
Findling et al with three comparison arms). Furthermore, a relatively higher dropout 
rate (43.1%) and discontinuation rate due to adverse reactions (14.4%) may have 
excluded potential participants responsive to aripiprazole. A higher treatment dose 
of aripiprazole (> 20 mg/day) did not show increased efficacy (effect size: -0.097, p = 
0.299), although an insufficient number of trials with a lower treatment dose 
prevented further analysis. Of three previous meta-analyses (Fountoulakis et al., 
2011; Meduri et al., 2016; Vieta et al., 2010), none showed positive results with the 
efficacy of aripiprazole at the endpoint; however, one study mentioned early efficacy 
for bipolar depression (Fountoulakis et al., 2011). Aripiprazole monotherapy did not 
significantly differ from haloperidol or lithium in the treatment efficacy of depressive 
symptoms during the acute phase, as assessed by reduced scores in the MADRS. In a 
short trial on combination therapy with aripiprazole in the acute stage, Quante et al 
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(Quante et al., 2010) reported that aripiprazole plus citalopram was beneficial in 
treating bipolar depression compared to a placebo plus citalopram. These results 
may demonstrate the potential efficacy of aripiprazole in treating bipolar depression, 
and further studies focusing on bipolar depression may help to clarify the efficacy of 
aripiprazole. 
For trials on mania with sufficient data for analysis, aripiprazole monotherapy 
was significantly superior to a placebo with a higher dose (> 20 mg/day), but not 
with a lower dose (< 20 mg/day) or shorter treatment duration (< 4 weeks). From 
response and remission rates as secondary outcomes in the acute stage, aripiprazole 
was significantly better than a placebo. For sub-groups without enough trials to allow 
for analysis, one study with a longer treatment group (> 4 weeks) (Tramontina et al., 
2009) and another trial (Vieta et al., 2008) reported that aripiprazole combination 
therapy in the acute stage showed significant efficacy. Previous systemic reviews and 
meta-analyses (Arbaizar et al., 2009; Brown et al., 2013; Fountoulakis et al., 2011; 
Meduri et al., 2016; Yildiz et al., 2015) reported significant efficacy in treating mania 
with aripiprazole, which is consistent with our results. Compared to the study 
focusing on mania (Brown et al., 2013), we used grouping to evaluate 
dose-dependent and time effects. As a result, our results suggest that a higher dose 
(> 20 mg/day) and longer treatment period (> 4 weeks) may achieve better outcomes 
for bipolar mania, although previous publications (Dhillon, 2012; Schatzberg and 
Nemeroff, 2009) suggested that a therapeutic dose of 15 to 30 mg/day may be 
appropriate for bipolar mania. In comparisons of aripiprazole monotherapy versus a 
placebo in acute mania, our meta-regression revealed that an older age was 
associated with a poorer outcome with aripiprazole treatment than with a placebo 
with a significant but relatively small effective coefficient ratio (coefficient = 0.0137, 
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p = 0.0081). A previous study investigating predictors for recovery from mania 
showed that an older age was associated with a faster recovery from mania (Tohen et 
al., 2003), although this may be not meaningful for our results due to the relatively 
small effect size. 
Few studies (Fountoulakis et al., 2011) have investigated relapse rates under 
aripiprazole treatment for BD. We focused on the relapse rates as preventive efficacy 
within acute or maintenance states. No significance differences in relapse rates were 
observed between aripiprazole monotherapy and a placebo in the acute stage of BD, 
however, combination aripiprazole therapy showed a better preventive effect as 
measured by relapse rates (OR: 0.522, p = 0.029) versus a placebo in the 
maintenance stage of BD. Although there were insufficient trials to allow for 
subgroup analysis of aripiprazole monotherapy versus a placebo in maintenance 
therapy, both studies (Keck et al., 2009; Muzina et al., 2008) showed promising 
efficacy of aripiprazole. Therefore, it may be more appropriate to use relapse rates as 
the primary outcome in the maintenance phase than in the acute phase in clinical 
practice, because the maintenance phase has a longer period of follow-up than the 
acute phase. Furthermore, our results differ from a previous meta-analysis (Miura et 
al., 2014) which demonstrated no significant efficacy in relapse rates in the 
maintenance state of BD. In summary, the current study clarifies the efficacy of 
relapse rates, and suggests that they can be applied to clinical practice in the future.  
We also analyzed the CGI-S as an alternative measurement of efficacy of 
aripiprazole treatment. Comparing aripiprazole monotherapy and a placebo in the 
acute stage of BD, aripiprazole was associated with significant improvements in the 
CGI-S than a placebo across manic/mixed and depressed states, and also with 
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aripiprazole monotherapy and a placebo in the maintenance stage. These results are 
comparable to previous studies (Brown et al., 2013; Fountoulakis et al., 2011) which 
reported categories of CGI, however further clinical trials are necessary for subgroup 
analysis within different categories of mood state. In three trials (Keck et al., 2009; 
Vieta et al., 2005; Young et al., 2009), aripiprazole was significantly better than other 
medications (haloperidol or lithium) in the CGI-S (effect size: -0.191, p = 0.003) with 
regards to treatment efficacy of BD during the acute phase. In addition, the efficacy 
of treatment for psychotic features is also important due to the effect on recovery in 
BD. Psychotic mania has been associated with longer periods of remission (Rosenthal 
et al., 1979), higher rates of relapse, worse social functioning, and occupational 
status (Tohen et al., 1990) compared to non-psychotic mania. Moreover, psychotic 
features are highly associated with suicide attempts in patients with BD (McGrady et 
al., 2017). Aripiprazole monotherapy tended to reduce PANSS scores compared to a 
placebo in the acute phase, indicating a beneficial effect in treating psychotic 
features. Another meta-analysis (Fountoulakis et al., 2009) also supports the 
usefulness of aripiprazole for psychotic symptoms during the acute manic and 
maintenance phases of BD, which is consistent with our results. 
Antipsychotic medications are associated with a wide range of potential adverse 
effects, including metabolic syndrome. A population-based cohort study (Chien et al., 
2010) found that the use of antipsychotics was hazardous for patients with BD 
suffering from diabetes. We comprehensively analyzed associations between 
aripiprazole and the metabolic syndrome/diabetes. Compared to a placebo in the 
acute phase, aripiprazole was significantly associated with a lower risk of elevated 
fasting glucose, increased appetite, and level of total cholesterol. No significant 
differences in levels of HDL, TG, BMI or body weight were found. In the maintenance 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
35 
 
stage of BD, aripiprazole was still not associated with significant differences in fasting 
glucose, increased body weight, level of total cholesterol, or level of TG. Of note, 
aripiprazole was associated with a significantly higher level of HDL than a placebo 
(effect size: -0.710, p = 0.002) with a mean increment of 2.662 mg/dl after 
aripiprazole treatment. HDL has been shown to be beneficial as a cardiovascular 
protector (Gomaraschi et al., 2016) and to exert anti-diabetogenic functions on beta 
cells of the endocrine pancreas (von Eckardstein and Widmann, 2014). In 
combination therapy, aripiprazole was associated with lower levels of fasting glucose 
and TG, and a smaller increase in body weight than a placebo. However, a significant 
increase in total cholesterol of 2 mg/dl was found in the aripiprazole group compared 
with a placebo. Considering the normal ranges of total cholesterol (< 200 mg/dl) and 
HDL (40-60 mg/dl), an increase in total cholesterol of 2 mg/dl may not be clinically 
meaningful. In conclusion, aripiprazole seems to be a safe therapeutic option with 
regards to metabolic profile. We then evaluated possibly associations between 
gastro-intestinal disturbances and aripiprazole treatment (Taylor, 2003) with regards 
to short-term nausea, vomiting, and constipation. Our result showed that 
aripiprazole should be used cautiously due to gastro-intestinal problems. In the acute 
stage, aripiprazole was significantly associated with higher rates of constipation, 
nausea, and vomiting than a placebo, although no harmful cases of diarrhea or 
dyspepsia were observed. When extending the follow-up period to the maintenance 
stage, aripiprazole continued to be associated with a higher incidence of diarrhea 
and dry mouth than a placebo. Our findings are inconsistent with a previous study 
(Brown et al., 2013), which suggested insignificant differences of rate of diarrhea 
compared to placebo, and clinicians should carefully explain these side effects before 
prescribing aripiprazole to patients with BD. 
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EPS is an undesirable adverse reaction to all antipsychotics, although atypical 
antipsychotics may have a lower risk than typical antipsychotics (Pierre, 2005). 
Aripiprazole was associated with a significantly higher incidence of EPS and 
hyper-salivation in the acute phase than a placebo. However, there were no 
significant differences in EPS among the patients receiving aripiprazole monotherapy 
and other medications (haloperidol or lithium). Specifically, aripiprazole was better 
than haloperidol, but not different than lithium. No significance differences were 
noted in tremors between haloperidol or lithium. Hence, aripiprazole may be 
beneficial compared to other medications, which is consistent with the findings of a 
previous meta-analysis (Brown et al., 2013) focusing on bipolar mania. Moreover, 
other undesirable symptoms including anxiety and akathisia should be addressed 
due to the high incidence of akathisia in several trials (El Mallakh et al., 2010; Thase 
et al., 2008). Aripiprazole was associated with higher rates of akathisia and anxiety 
than a placebo in the acute stage, and a higher rate of akathisia in the maintenance 
stage. However, compared to other medications (lithium or haloperidol), there was 
no significant difference in akathisia (effect size: -0.130, p = 0.696). Therefore, 
aripiprazole may not be as hazardous as previously thought, and further clinical trials 
are warranted to investigate this issue, especially for comparisons with 
anticonvulsants or other second-generation antipsychotics.  
For other adverse reactions including, dizziness, agitation, headache, light 
headedness, and upper respiratory tract infection, there were no significant 
differences between aripiprazole and a placebo in the acute or maintenance stage. 
However, aripiprazole was associated with significantly higher incidence rates of 
fatigue, insomnia, over-sedation, and pain in the extremities compared to a placebo. 
However, there was no significant difference in over-sedation between aripiprazole 
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and a placebo in the maintenance phase. There was also no significant difference in 
the incidence of headache between aripiprazole and haloperidol or lithium. We 
assessed adherence using dropout rates and rates of discontinuation due to side 
effects. Compared with a placebo in the acute stage, no significance was noted for 
aripiprazole in dropout rate, however there was a significantly lower dropout rate 
with aripiprazole in the maintenance stage. In combination therapy, there was no 
significant difference between aripiprazole and a placebo in dropout rate. The results 
of recent meta-analyses (Brown et al., 2013; Meduri et al., 2016; Yildiz et al., 2015) 
are consistent with our findings with regards to drop-out rates. However, aripiprazole 
was associated with a higher rate of discontinuation due to side effects than a 
placebo in acute and maintenance stages, which may have been due to the relatively 
higher incidence of intolerable side effects such as akathisia and gastro-intestinal 
disturbances. However, there were no significant differences in discontinuation rates 
due to side effects between aripiprazole and lithium or haloperidol, which is 
consistent with the study by Brown et al (Brown et al., 2013). Our results suggest that 
aripiprazole may not be more hazardous than other medications  
A strength of the current study is that we focused our analysis on aripiprazole 
treatment across mania to depression in BD. Our results show inconsistencies in the 
efficacy or adverse reactions of aripiprazole treatment, which is also a strength. 
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Limitations: 
There are several limitations to this study. First, the lack of trials (fewer than 
three) for subgroup analysis, including aripiprazole monotherapy versus other 
medications in the maintenance stage, aripiprazole combination therapy versus 
other medications in the acute and maintenance stages, and aripiprazole 
combination therapy versus a placebo in the acute stage, limits the strength of our 
results. Second, due to language limitations, we may have missed articles published 
in other languages. Third, we cannot rule out the possible confounding effects of the 
concomitant use of other medications with combination therapy of aripiprazole and 
a placebo/other medications. Fourth, due to the limited number of included studies, 
we could not undertake meaningful meta-regression analyses of specific comparison 
groups (maintenance stage, etc.) to investigate the influence of variables that may 
have influenced the observed results and the heterogeneity of these findings. Finally, 
due to the absence of head to head studies considering the advantages or 
disadvantages of aripiprazole over other second-generation antipsychotics, we could 
not perform meta-analyses between them, which may be a concern in clinical 
practice. 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
39 
 
Conclusion: 
In summary, the current meta-analysis adds to the current knowledge on 
treating bipolar mania, especially with regards to secondary outcomes and safety 
profiles. Our results showed that aripiprazole was beneficial in preventing bipolar 
mania. Unfortunately, aripiprazole has a minimal effect on bipolar depression. In 
addition, aripiprazole has outstanding tolerability with regards to the metabolic 
syndrome, EPS, and dropout rates. Furthermore, aripiprazole may be beneficial in 
clinical practice for akathisia compared to haloperidol or lithium, although it was 
more hazardous than a placebo. Caution should be taken with regards to 
gastro-intestinal disturbances when prescribing aripiprazole. Future trials should 
carefully detail information on the incidence of adverse events and treatment 
efficacy compared to other medications, especially second-generation antipsychotics. 
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Figure legends 
Figure 1: Flowchart of the current meta-analysis 
Figure 1 The databases used, the inclusion criteria, the search 
strategy and selection process of the current meta-analysis 
 
Figure 2 (A) Forest plot of the meta-analysis of differences in changes in 
depressive symptoms in patients receiving aripiprazole and a placebo 
in acute bipolar depression; (B) forest plot of the meta-analysis of 
differences in changes in manic symptoms in patients receiving 
aripiprazole and a placebo in acute bipolar mania; (C) forest plot of 
the meta-analysis of differences in changes in the general severity in 
patients with bipolar disorder receiving aripiprazole and a placebo in 
the maintenance stage 
Figure 2A There were no significant differences between changes in 
depressive symptoms between the patients receiving aripiprazole or 
a placebo in acute bipolar depression (Hedges’ g=-0.127, 95% 
CI=-0.257 to 0.002, p=0.054); Figure 2B There was a significant 
improvement in manic symptoms in the patients receiving 
aripiprazole than those receiving a placebo in acute bipolar mania 
(Hedges’ g=-0.299, 95% CI=-0.476 to -0.123, p=0.001). Figure 2C 
There was a significant improvement in the general severity in 
patients with bipolar disorder receiving aripiprazole than in those 
receiving a placebo in the maintenance stage (Hedges’ g=-0.483, 95% 
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CI=-0.674 to -0.292, p<0.001). 
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Table 1: Summary of characteristics of studies in current 
meta-analysis 
 
Study 
Criter
ia 
Diagnosis/m
ood state 
Comparison N 
Dropo
ut (%) 
Gender 
(%fema
le) 
Ag
e 
Phase 
Countr
y 
Keck, P.E. 
(2003) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Placebo 
13
0 
13
2 
58.0 
79.0 
55.0 
58.0 
40.
5 
40.
5 
Acute USA 
Vieta, E. 
(2005) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Haloperidol  
17
5 
17
2 
49.4 
71.8 
56.6 
66.9 
42.
6 
41.
0 
Acute 
Multip
le 
countr
y 
Sachs, G. 
(2006) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Placebo 
13
7 
13
5 
45.0 
48.0 
50.0 
53.0 
37.
3 
40.
4 
Acute USA 
Keck, P.E. 
(2007) 
DSM-
IV 
BD-I 
Aripiprazole 
Placebo 
77 
81 
91.0 
92.8 
62.0 
72.0 
39.
0 
40.
3 
Maintena
nce 
Multip
le 
countr
y 
Thase, 
M.E. 
(2008)-st
udy A 
DSM-
IV 
BD-I, 
depressed 
Aripiprazole 
Placebo 
18
6 
18
8 
46.8 
35.1 
62.0 
63.0 
39.
0 
39.
0 
Acute USA 
Thase, 
M.E. 
(2008)-st
udy B 
DSM-
IV 
BD-I, 
depressed 
Aripiprazole 
Placebo 
18
7 
18
8 
41.2 
29.8 
60.0 
60.0 
41.
0 
40.
0 
Acute USA 
Muzina, 
D.J. 
(2008) 
DSM-
IV 
BD-I, rapid 
cycling 
Aripiprazole 
Placebo 
14 
14 
79.0 
100.0 
64.3 
71.4 
37.
6 
38.
8 
Maintena
nce 
USA 
Vieta, E. 
(2008) 
DSM-
IV 
BD-I, 
manic/mixe
Aripiprazole 
+ Li or Val  
25
3 
n/a 
52.0 
58.0 
42.
2 
Acute 
Multip
le 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
54 
 
d Placebo + Li 
or Val 
13
1 
41.
7 
countr
y 
Keck, P.E. 
(2009) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Li 
Placebo 
15
5 
16
0 
16
5 
20.0 
15.0 
19.0 
49.0 
48.0 
48.0 
39.
6 
39.
6 
39.
8 
Acute USA 
Findling, 
R.L. 
(2009) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
10 mg 
Aripiprazole 
30 mg 
placebo 
98 
99 
99 
14.3 
22.2 
23.2 
46.9 
48.5 
43.4 
13.
7 
13.
3 
13.
3 
Acute USA 
Tramonti
na, S. 
(2009) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Placebo 
18 
25 
5.6 
4.0 
66.7 
44.0 
11.
7 
12.
2 
Acute Brazil  
Young, 
A.H. 
(2009) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
haloperidol  
Placebo 
16
7 
16
5 
15
3 
43.1 
42.4 
45.1 
57.0 
56.0 
54.0 
40.
5 
41.
6 
40.
2 
Acute 
Multip
le 
countr
y 
Quante, 
A. 
(2010) 
DSM-
IV 
BD-I or II, 
depressed 
Aripiprazole 
+ (Li or Val) 
+ 
Citalopram 
Placebo + (Li 
or Val) + 
Citalopram 
12 
11 
n/a 
45.4 
50.0 
53.
6 
48.
2 
Acute 
Germa
ny 
El 
Mallakh, 
R.S. 
(2010) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
15 mg 
Aripiprazole 
30 mg 
Placebo 
13
1 
13
6 
13
4 
57.0 
60.0 
60.0 
50.0 
54.0 
51.0 
39.
3 
41.
4 
40.
6 
Acute 
Multip
le 
countr
y 
Woo, Y.S. DSM- BD-I, Aripiprazole 40 42.5 67.5 38. Maintena Korea 
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(2011) IV manic/mixe
d 
+ Val 
Placebo + 
Val 
43 41.9 55.8 3 
38.
3 
nce 
El 
Mallakh, 
R.S. 
(2012) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Li 
25 
38 
75.0 
65.8 
60.0 
50.0 
37.
2 
41.
2 
Maintena
nce 
USA 
Carlson, 
B.X. 
(2012) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
+ 
Lamotrigine 
Placebo + 
Lamotrigine 
17
8 
17
3 
63.5 
69.4 
67.4 
62.4 
39.
6 
38.
6 
Maintena
nce 
USA 
Jeong, 
H.G. 
(2012) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
+ Val 
Haloperidol 
+ Val 
28 
14 
7.1 
7.1 
67.9 
57.1 
37.
2 
36.
1 
Acute Korea 
Findling, 
R.L. 
(2012) 
DSM-
IV 
BD-I or II 
Aripiprazole 
+ other 
psychostimu
lant 
Placebo + 
other 
psychostimu
lant 
30 
30 
80.0 
100.0 
37.0 
23.0 
7.1 
6.7 
Maintena
nce 
USA 
Findling, 
R.L. 
(2013) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
10 mg 
Aripiprazole 
30 mg 
Placebo 
75 
71 
64 
54.7 
69.0 
81.3 
n/a 
13.
6 
13.
1 
13.
3 
Maintena
nce 
USA 
Kanba, S. 
(2014) 
DSM-
IV 
BD-I, 
manic/mixe
d 
Aripiprazole 
Placebo 
12
8 
13
0 
43.8 
50.8 
57.4 
60.0 
37.
5 
37.
8 
Acute 
Multip
le 
countr
y 
 
Abbreviation:  n/a: not available; Bipolar I disorder: BD-I; Bipolar II disorder: BD-II; DSM-IV: 
Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV: Diagnostic and Statistical 
Manual of Mental Disorders, 4
th
 Edition; n/a: not applicable; Li: l ithium; Val: valproate 
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Table 2: Summary of comparison between current study and 
two recently meta-analysis on aripiprazole 
 
Articles Current Brown, R. et al. 2013 
Meduri, M. et al. 
2016 
No. of included 
articles 
20 10 22 
Open labeled 
trails  
Not included Not included 5 
RCCTs 2 2 2 
RPCTs 20 9 15 
End of search January 23
th 
,2017 July 31
th
 ,2013 June 30
th
,2015 
Mood states manic/mixed, depressed manic/mixed 
manic/mixed, 
depressed 
MA of acute phase Included Included Included 
MA of maintenance 
phase 
Included n/a n/a 
MA of efficacy (result) 
changes of 
severity 
(depression) 
NS (Arp vs. Pla, mono-tx in 
AP)  
NS (Arp vs. Hal or Li, 
mono-tx in AP) 
NS
2
 (Arp vs. Pla, 
mono-tx) 
NS
2
 (Arp vs. Hal or Li, 
mono-tx) 
n/a 
changes of 
severity 
(mania) 
Favor Arp (Arp vs. Pla, 
mono-tx in AP) 
n/a (Arp vs. Hal or Li, 
mono-tx) 
Favor Arp (Arp vs. Pla, 
mono-tx) 
NS (Arp vs. Hal or Li, 
mono-tx) 
Favor Arp (Arp vs. 
Pla, mono-tx) 
NS (Arp vs. Hal or Li, 
mono-tx) 
changes of 
severity 
(psychotic 
features) 
Favor Arp (Arp vs. Pla, 
mono-tx in AP) 
Favor Arp (Arp vs. Pla, 
mono-tx ) 
NS
2 
(Arp vs. Hal or Li, 
mono-tx) 
n/a 
response rates 
Favor Arp in mania (Arp vs. 
Pla, mono-tx in AP) 
NS (Arp vs. Hal or Li, 
mono-tx) 
Favor Arp in mania 
(Arp vs. Pla, mono-tx ) 
NS in mania (Arp vs. 
Hal or Li, mono-tx) 
Favor Arp in mania 
(Arp vs. pla, 
mono-tx) 
NS in mania (Arp vs. 
Hal or Li, mono-tx) 
remission rates Favor Arp in mania (Arp vs. NS in mania (Arp vs. n/a 
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Pla, mono-tx in AP) Pla, mono-tx ) 
relapse rates 
Favor Arp (Arp vs. Pla, 
com-tx in MP) 
n/a n/a 
CGI-S 
Favor Arp (Arp vs. Pla, 
mono-tx in AP) 
Favor Arp (Arp vs. Pla, 
mono-tx in MP) 
Favor Arp (Arp vs. Hal or Li, 
mono-tx in AP) 
Favor Arp in mania 
(Arp vs. Pla, mono-tx ) 
NS in depression (Arp 
vs. Pla, mono-tx ) 
Favor Arp overall
1 
(Arp 
vs. Pla, mono-tx ) 
NS in mania
2 
(Arp vs. 
Hal or Li, mono-tx ) 
NS in depression
2 
(Arp 
vs. Hal or Li, mono-tx ) 
n/a 
MA of adverse drug reaction 
Metabolic profile 
Increased appetite, Sugar 
AC, BMI, BW change, level 
of HDL, level of TG 
weight gain n/a 
Adherenc es 
profile 
dropout rates, Dis SE dropout rates, Dis SE n/a 
Gastro-intestinal 
profile 
constipation, diarrhea, 
nausea vomiting, dyspepsia, 
dry mouth 
nausea, dyspepsia, 
vomiting, constipation, 
diarrhea 
n/a 
EPS EPS, salivation, tremor EPS, tremor n/a 
Other ADRs 
agitation, akathisia, anxiety, 
dizziness over-sedation, 
light-headedness, UTI, 
insomnia, headache, fatigue 
dyspnea, pain extremities, 
back pain 
hypertension 
akathisia, headache, 
anxiety, insomnia, 
light-headedness, pain 
extremities, 
over-sedation 
n/a 
 
1: mania plus depression 
2: less than three trials 
 
Abbreviation: n/a: not available; MA: meta-analysis; ADR: adverse reaction; 
randomized placebo-controlled trials; RPCTs: randomized placebo-controlled trials; 
RCCTs: randomized case-controlled trials; CGI-S: The Clinical Global Impression – 
Severity scale; EPS: extrapyramidal symptoms; Sugar AC: blood sugar before meals; 
BMI: body mass index; BW: body weight; HDL; high density lipoprotein; TG: total 
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cholesterol, triglyceride; Dis SE: rates of discontinuation of trials due to side effect; 
UTI: upper respiratory tract infection; vs.: versus; Arp: aripiprazole; Hal: haloperidol; 
Li: lithium; Pla: placebo; mono-tx: monotherapy; com-tx: combination therapy; AP: 
acute phase; MP: maintenance phase; NS: non-significance 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
59 
 
   Table 3: Summary of comparison of adverse reactions in 
current meta-analysis 
 
Adverse Reaction 
Acute phase 
Maintenance 
phase 
Acute/Maintenance phase 
ARP 
monotherapy 
vs PLA 
ARP 
monotherapy 
vs PLA 
ARP 
combination 
therapy vs PLA 
ARP combination 
therapy/monotherapy vs 
other Rx 
Metabolic profile     
fasting glucose 
Worse by 
PLA 
N.S. N.S. n/a 
BMI N.S. n/a n/a n/a 
BW N.S. N.S. n/a n/a 
HDL N.S. Worse by ARP n/a n/a 
T-chol 
Worse by 
PLA 
N.S. Worse by ARP n/a 
TG N.S. N.S. N.S. n/a 
Increased 
appetite 
Worse by 
PLA 
n/a n/a n/a 
Adherences profile    n/a 
dropout rate N.S. Worse by PLA N.S. N.S. 
dis-side-effect 
Worse by 
ARP 
Worse by ARP n/a N.S. 
Gastro-intestinal 
profile 
   n/a 
constipation 
Worse by 
ARP 
n/a n/a n/a 
diarrhea N.S. Worse by ARP n/a n/a 
nausea 
Worse by 
ARP 
n/a n/a n/a 
vomiting 
Worse by 
ARP 
n/a n/a n/a 
dyspepsia N.S. n/a n/a n/a 
dry mouth n/a Worse by ARP n/a n/a 
Other profile    n/a 
agitation N.S. n/a n/a n/a 
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akathisia 
Worse by 
ARP 
Worse by ARP n/a N.S. 
anxiety 
Worse by 
ARP 
n/a n/a n/a 
dizziness N.S. n/a n/a n/a 
over-sedation 
Worse by 
ARP 
n/a n/a n/a 
l ight-headedness N.S. n/a n/a n/a 
headache N.S. N.S. N.S. N.S. 
fatigue 
Worse by 
ARP 
n/a n/a n/a 
insomnia 
Worse by 
ARP 
n/a n/a n/a 
pain extremities 
Worse by 
ARP 
n/a n/a n/a 
EPS 
Worse by 
ARP 
n/a n/a N.S. 
sialorrhea 
Worse by 
ARP 
n/a n/a n/a 
tremor n/a n/a n/a N.S. 
URI n/a N.S. n/a n/a 
 
Abbreviation: n/a: not available; BMI: body mass index; BW: body weight; HDL: high density 
l ipoprotein; T-chol: total cholesterol ; TG: triglyceride; ARP: Aripiprazole; PLA: placebo; NS: 
Non-significant difference; dis-side-effect Rates of discontinuation due to side effect; EPS: 
extrapyramidal symptoms; URI: upper respiratory-tract infection; Rx: medication 
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